DNA Nanobots Appoints Dr. John C. Byrd to Scientific Advisory Board
DNA Nanobots, a leader in biotechnology specializing in DNA nanoparticles for targeted therapeutics, has announced the addition of Dr. John C. Byrd, M.D., to its Scientific Advisory Board (SAB). Dr. Byrd is an internationally recognized physician-scientist who has played a key role in the translational research and development of groundbreaking therapies for blood cell cancers. Having collaborated with DNA Nanobots’ founding scientists for over a decade, Dr. Byrd will continue to support the company’s pre-clinical development efforts. He brings invaluable expertise in translational medicine to help advance DNA Nanobots’ therapeutic pipeline and provide guidance on customizable solutions for biopharma partners focused on enhancing the targeted delivery of therapeutic payloads.
Dr. John C. Byrd, M.D., a globally recognized expert in hematologic malignancies, has joined the scientific advisory board (SAB) of DNA Nanobots, a leading biotechnology company specializing in DNA nanoparticles for targeted therapeutics. Dr. Byrd, who is currently the Chair of the Department of Internal Medicine at the University of Cincinnati, holds the prestigious Gordon and Helen Hughes Taylor Chair. He was previously a Distinguished University Professor at Ohio State University and has an extensive career focused on translational research in blood cancers. In addition to his academic roles, Dr. Byrd serves as the principal and Chief Medical Officer of Beat AML, a company affiliated with the Leukemia and Lymphoma Society.
With over 600 publications, Dr. Byrd is a prominent figure in the field of hematologic oncology. He leads a translational laboratory dedicated to studying hematologic malignancies, such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Dr. Byrd has played pivotal roles in the clinical development and FDA approval of several breakthrough therapies, including rituximab and ibrutinib, two medicines that have revolutionized the treatment of blood cancers. His expertise in clinical development, regulatory strategies, and drug approval processes will be invaluable as DNA Nanobots continues to advance its own therapeutic pipeline and explore customizable drug delivery solutions.
“I am excited to formalize my long-term relationship with DNA Nanobots and its scientific founders as a member of its scientific advisory board. I believe that their programmable DNA nanoparticle technology offers great promise to improve the way oncology drugs and immunotherapies are designed and developed, ultimately leading to more effective therapies,” Dr. Byrd stated. His endorsement highlights the potential of DNA Nanobots’ innovative approach to revolutionize drug development, particularly in oncology.
DNA Nanobots is at the forefront of creating advanced DNA nanoparticles capable of delivering therapeutic payloads with high precision. Recently, the company secured a portfolio of intellectual property related to DNA origami for biomedical applications from The Ohio State University. This technology was pioneered by Dr. Carlos E. Castro, Ph.D., Professor and Ralph W. Kurtz Chair in Mechanical Engineering at Ohio State, and his research team.
Dr. Castro, who also serves on DNA Nanobots’ scientific advisory board, expressed his enthusiasm for Dr. Byrd’s involvement. “We’ve had a great working relationship with Dr. Byrd for over ten years, and he has been instrumental in guiding our Nanobot platforms for pre-clinical development. We look forward to his expertise and continued collaboration,” said Dr. Castro.
Dr. Byrd’s appointment further strengthens DNA Nanobots’ efforts to leverage cutting-edge technology in the development of novel therapeutics. His experience will be critical in advising the company on the pre-clinical development of its cancer therapeutics and guiding clinical trial design, regulatory strategies, and performance improvement for its biopharma partners.
“We are extremely fortunate to have Dr. John Byrd on our team to advise on the pre-clinical development of our own cancer therapeutics, inform clinical trial design, and regulatory strategies, and improve performance for our biopharma partners,” said DNA Nanobots CEO Jim Lynch, Ph.D. “Many therapeutics show promise in laboratory settings but fail when tested in the clinic. With Dr. Byrd’s guidance, we aim to improve the odds and enhance the success rate of our therapies.”
DNA Nanobots’ unique approach to drug delivery revolves around its platform technology, which is focused on engineering customizable DNA nanoparticles. These nanoparticles are designed to deliver a variety of therapeutics with high precision to specific tissues, offering the potential for more effective and less toxic treatments, particularly in oncology and rare diseases. The company’s technology holds great promise not only for its own drug development pipeline but also for partnerships with biopharma companies seeking advanced drug delivery solutions.
In addition to its innovative nanoparticle platform, DNA Nanobots is actively developing its pipeline of cancer therapeutics, targeting diseases such as AML and other cancers that are difficult to treat with conventional methods. The company’s commitment to developing more effective therapies and improving clinical outcomes is reflected in its partnership with prominent experts like Dr. Byrd, whose experience in drug development and clinical trials is a valuable asset.
As the Nanobots continues to push the boundaries of drug delivery technology, Dr. Byrd’s guidance will play a key role in refining the company’s approach, advancing pre-clinical efforts, and navigating the regulatory landscape. With the support of leading experts like Dr. Byrd, this Nanobots is poised to make significant strides in the development of targeted therapies that could ultimately change the treatment landscape for cancer and rare diseases.
About DNA Nanobots
DNA Nanobots is a pioneering biotechnology platform company focused on developing customizable DNA nanoparticles for targeted drug delivery. By engineering precision tissue-targeted solutions, this Nanobots works with biopharma partners to deliver a range of therapeutics more effectively. The company is also developing its own pipeline of cancer therapeutics and treatments for rare diseases, aiming to improve the lives of patients by enhancing the precision and efficacy of drug delivery systems.
